Fig. 2.

Schematic of transdermal microneedle patch delivery (A) and intracellular pathway (B) of genome editing agent (Cas9) nanocomplex and glucocorticoid nanoparticle (dexamethasone delivered from the patch) to treat the inflammatory skin diseases. T7 endonuclease I assay of indels (method to validate CRISPR reagents) introduced into the nod-like receptor family, pyrin domain-containing 3 (NLRP3) locus of DC (dendritic cell) 2.4 cells (C) and 3T3 cells (D) transfected with the two nanoparticles. The figure was

reproduced from ref. [38]. Copyright Science Advance 2021